# A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)

> **NCT07592819** · NA · NOT_YET_RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 367 (estimated)

## Conditions studied

- Pancreas Adenocarcinoma (MSI-H)
- Pancreatic Cancer Resectable

## Interventions

- **DRUG:** mFOLFIRINOX (modified FOLFIRINOX)

## Key facts

- **NCT ID:** NCT07592819
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2030-05
- **Final completion:** 2031-11
- **Target enrollment:** 367 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07592819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07592819, "A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT07592819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*